Abstract 4297
Background
Anxiety and distress may be experienced by cancer patients diagnosed with melanoma throughout their diagnosis and treatment. Beaumont Hospital, Dublin is a designated cancer centre and a proposal to develop an onsite melanoma patient support group (MPSG) in collaboration with the Skin Oncology CNSp, and the Cancer Nurse, Daffodil Centre, Beaumont Hospital was agreed. Aims/Objectives: To assess the interest in attending a professionally facilitated MPSG. To ascertain what type of group would benefit most. To ascertain the themes required to meet the needs of the group. To offer a supportive, safe environment for meeting and sharing experiences. To create an awareness of the support required by patients diagnosed with melanoma.
Methods
Initial planning meeting between the Skin Oncology CNS and the Cancer Nurse, resulted in an agreement to develop a MPSG. A target population was identified and the practicalities and commitment involved in co-facilitating a support group were identified. Group governance was developed. An expression of interest letter and a questionnaire was sent to the target population, specific themes were incorporated to assist development of the support group and manage its format and content.
Results
Patient responses identified a format for the support group incorporating educational and emotional support. Group rules were established and adhered to, with regular evaluation and discussion taking place allowing change to be incorporated as required. Six meetings took place in 2018/2019.
Conclusions
Future plans include: Maintain stability of the group. Continue meeting every two months. Attract new members. Review of group by questionnaire in relation to specific patient interests.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract